AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 151 min read$CUE

Ray Sumita sold $52K of CUE

Ray Sumita (Chief Legal Compliance Officer) sold 1,844 shares of Cue Biopharma, Inc. (CUE) at $28.05 on 2026-10-12.

Original reporting
SEC EDGAR · Ray Sumita
Published Oct 15, 2026, 1:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CUE
Bearish
medium confidence
Mentioned
$CUE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CUEBearishLow
01

Why it matters

The modest sale may cause short‑term price softness but is unlikely to move the stock significantly given the small dollar amount.

02

Market read

Primary relevance is to Cue Biopharma shareholders; broader market impact is minimal.

03

What to watch

The insider retained a sizable position (over 116k shares), suggesting continued confidence.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a recent open‑market sale by a senior compliance officer.

Company-level read

Ticker impact

$CUEBearishMedium confidence
Context

Chief Legal Compliance Officer Ray Sumita sold 1,844 shares of Cue Biopharma at $28.05 per share, reducing his stake to 116,701 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

The transaction size is small ($52K) but involves a senior officer, which can be viewed as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector; typical insider sales are not sector‑wide drivers.

Regional

No significant regional effect; the filing is U.S.‑focused.

Global

Limited global relevance; only relevant to investors tracking Cue Biopharma.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • company
    Cue Biopharma, Inc.

    Biopharma company listed on Nasdaq under ticker CUE.

  • person
    Ray Sumita

    Chief Legal Compliance Officer at Cue Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CUE insider trading history →

Related articles

SEP 26
$CUEMedAI 8/10

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma (CUE) reported positive Phase 2 results for CUE-221 in treating chronic hives, with 54% of patients achieving complete hive resolution vs. 11% on placebo. The drug showed sustained relief 12 weeks post-treatment, with 60% of patients in the highest-dose group remaining hive-free. No serious adverse events were reported. The company plans a Phase 2b/3 study and has $67.4M in cash after recent financing.

insidermonkey.com3 min
SEP 21
$CUEMedAI 9/10

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling stu

SEC EDGAR 8-K2 min
SEP 21
$CUEHighAI 8/10

Why is Cue Biopharma stock surging today?

Cue Biopharma (CUE) stock surged 41.6% in pre-market trading after positive Phase 2 trial results for CUE-221, its anti-IgE monoclonal antibody, in treating chronic spontaneous urticaria. The trial met primary and secondary endpoints with statistical significance and a favorable safety profile. The data suggests CUE-221 may offer advantages over the current standard of care, omalizumab (XOLAIR®). B. Riley Securities initiated coverage with a Buy rating.

investing.com2 min
AUG 14
$CUEMed

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications • Completed a $50 million private placement (PIPE) to further f

SEC EDGAR 8-K6 min